ACM
RYTM icon

ACT Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

ACT Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,500
Closed -$114K – 84
2022
Q2 		$114K Hold
27,500
– – 0.16% 48
2022
Q1 		$317K Hold
27,500
– – 0.34% 43
2021
Q4 		$274K Sell
27,500
-3,500
-11% -$39.3K 0.2% 58
2021
Q3 		$405K Hold
31,000
– – 0.21% 65
2021
Q2 		$607K Buy
+31,000
New +$644K 0.31% 59

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACT Capital Management's RYTM Position: Q3 2022 in Review

ACT Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2022, closing a stake of 27,500 shares — an estimated $114K sold.

ACT Capital Management first reported a position in RYTM in Q2 2021 and held it in 5 quarters. The position peaked at $607K in Q2 2021. 101 funds tracked by Wall St. Rank hold RYTM as of Q3 2022.

  • ACT Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • ACT Capital Management sold 27,500 Rhythm Pharmaceuticals shares in Q3 2022, an estimated $114K.
  • ACT Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • ACT Capital Management's Rhythm Pharmaceuticals position peaked at $607K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.